Dr Lal PathLabs beats in Q1; ICICI lifts target to Rs 1,690 but cuts rating to Hold
Patient volumes rose 8.2% year on year and sample volumes grew 10.7%, while revenue per patient increased about 10%. ICICI Securities lifted FY27 and FY28 earnings estimates and raised its target price, but downgraded the stock on valuation concerns.
What happened
Dr. Lal PathLabs · Dr Lal PathLabs beat Q1 FY27 expectations as network additions, specialised tests and CGHS pricing lifted volumes and revenue per patient.
Key facts
- Patient volumes grew 8.2% YoY
- Sample volumes rose 10.7% YoY
- Average revenue per patient increased about 10% YoY
- CGHS price revision contributed about 2-3%
- FY27 revenue-growth guidance upgraded to mid-teens
- FY27E EPS raised about 9%
- FY28E EPS raised about 5%
- Target price raised to Rs 1,690 from Rs 1,460
Why this matters
The combination of rising volumes and improved revenue per patient underscores the strategic value of network expansion, higher-value test mix and partnerships that deepen patient capture.
What to watch
- Quarterly patient-volume and sample-volume growth versus the reported 8.2% and 10.7% rates.
- Revenue per patient trend, especially whether approximately 10% growth remains sustainable.
- EBITDA margin movement from utilization gains versus employee, logistics, reagent and marketing costs.
- Management commentary on preventive-health demand, specialized-test mix and geographic expansion.
- Peer pricing actions and competitive intensity in home collection and organized diagnostics.
- Additional consensus EPS upgrades and whether the market price approaches or exceeds Rs 1,690 target.
- Prioritize expansion of high-value specialized, preventive and chronic-care test offerings to protect revenue per patient.
- Use rising sample volumes to improve lab utilization and collection-network productivity rather than relying on aggressive price increases.
- Defend metropolitan market share against hospital chains, regional laboratories and digital-health aggregators through turnaround time, clinician relationships and home collection.
- Maintain disciplined capital allocation, as a Hold downgrade signals incremental investors may demand clearer returns from expansion spending.